Insider activity at Anixa Biosciences (NASDAQ: ANIX) took a notable turn as director Lewis H. Titterton Jr. increased his direct stake in the biotechnology firm. According to a filing submitted to the Securities and Exchange Commission, Mr. Titterton acquired 2,836 shares of the company's common stock on June 16, 2026. The transaction was settled at a price of $2.64 per share, resulting in a total investment of $7,487. This direct purchase brings his total direct holdings to 972,170 shares.
The timing of the acquisition coincides with a period of recent corporate activity and financial reporting for Anixa Biosciences. The company recently reported a net loss of $2.5 million, or $0.07 per share, for its fiscal second quarter that concluded on April 30, 2026. Operational cash flows for the period were negative, totaling $1.7 million. Despite these operational challenges, the company maintained a cash and investment position of $13.7 million at the end of the reporting period.
Market reaction to the stock has been volatile, with the share price showing a significant return of 11% over the last week prior to the filing. However, valuation metrics present a mixed picture. Analysis suggests that the stock may be overvalued at current levels, despite the company holding more cash than debt on its balance sheet. This financial structure is noted as one of several key insights regarding the company's standing.
On the regulatory and pipeline front, Anixa Biosciences has secured significant intellectual property milestones. The Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering the company's ovarian cancer vaccine technology, which is licensed from the Cleveland Clinic. Additionally, the company received a Mexican patent for its breast cancer vaccine, securing intellectual property protection in that jurisdiction through 2040. Clinical data from the Phase 1 trial of its CAR-T therapy for recurrent ovarian cancer, known as lira-cel, has shown promising survival outcomes, with several patients surviving beyond the expected median. The therapy was also presented at the International Society for Cell & Gene Therapy 2026 Annual Meeting, detailing the current status and design of the clinical trial.
Following the release of the recent financial results, H.C. Wainwright reiterated a Buy rating for Anixa Biosciences, setting a price target of $7.00. The analyst firm's stance contrasts with the recent valuation concerns, highlighting the divergence between operational performance and market expectations in the biotechnology sector.